Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics:

• Mechanisms of endocrine resistance; incidence of ESR1 mutations in breast cancer (0:00)
• Testing methods for ESR1 mutations in patients with breast cancer; therapeutic options for patients with ESR1-mutant breast cancer (3:59)
• General overview of proteolysis-targeting chimeras (PROTACs); comparison of PROTAC estrogen receptor (ER) degraders and selective ER degraders (7:39)
• Early-phase data with vepdegestrant monotherapy or in combination with CDK4/6 inhibitors in ER-positive, HER2-negative metastatic breast cancer (mBC) (11:54)
• Phase III VERITAC-2 trial of vepdegestrant versus fulvestrant in ER-positive, HER2-negative mBC previously treated with endocrine therapy and a CDK4/6 inhibitor (17:48)
• Ongoing clinical trials evaluating vepdegestrant in novel combinations or treatment settings; other clinical applications of PROTACs (26:08)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics:

• Introduction: About This Program (0:00)
• Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10)
• Potential Treatment Benefits of CAR T-Cell Therapy (10:35)
• CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32)
• Finding Information About CAR T; Clinical Trials (42:17)
• Financial Issues; Risk of Infection (48:11)
• Coping with Anxiety; Healing and Moving On (55:17)

Educational and presenter information

Featuring slide presentations and related discussion from Prof Francois-Clement Bidard, Dr Hope S Rugo, Dr Rebecca Shatsky and Dr Seth Wander, including the following topics:

• Optimal approach to biomarker testing for patients with ER-positive metastatic breast cancer (mBC) (0:00)
• Case: A woman in her early 70s with recurrent ER-positive, HER2-negative mBC receives elacestrant (15:15)
• Case: A woman in her early 60s with ER-positive, HER2-low, PIK3CA-mutated mBC receives inavolisib-based therapy and experiences no disease progression for 24 months (18:02)
• Role of oral selective estrogen receptor degrader (SERD) monotherapy in the treatment of progressive ER-positive, HER2-negative mBC (26:26)
• Case: A woman in her mid 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (44:12)
• Case: A woman in her early 50s with recurrent HR-positive, HER2-negative, PIK3CA-mutant mBC receives capivasertib and fulvestrant (45:33)
• Potential novel applications of oral SERDs in the management of ER-positive, HER2-negative breast cancer (51:25)
• Case: A woman in her mid 50s with recurrent ER-positive, HER2-negative, PIK3CA-mutated mBC experiences disease progression 18 months after starting first-line letrozole and ribociclib (1:03:46)
• Case: A woman in her mid 50s with ER-positive, HER2-negative breast cancer undergoes serial ctDNA monitoring during first-line therapy (1:06:54)
• Tolerability and other practical considerations with oral SERDs (1:14:30)
• Case: A woman in her early 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (1:33:26)
• Case: A woman in her early 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (1:37:38)

CME information and select publications